Blodgett Wealth Advisors LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)

Blodgett Wealth Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 4,788 shares of the company’s stock after selling 96 shares during the quarter. Johnson & Johnson comprises about 0.7% of Blodgett Wealth Advisors LLC’s investment portfolio, making the stock its 25th biggest holding. Blodgett Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $776,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JNJ. Innealta Capital LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $27,000. MFA Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $43,000. Fairfield Financial Advisors LTD acquired a new stake in Johnson & Johnson in the second quarter valued at $46,000. Fairway Wealth LLC grew its holdings in Johnson & Johnson by 217.1% in the second quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after purchasing an additional 228 shares during the last quarter. Finally, Quarry LP acquired a new stake in Johnson & Johnson in the second quarter valued at $49,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. TD Securities decreased their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $163.45 on Wednesday. The stock’s 50-day moving average is $163.14 and its 200-day moving average is $154.84. The company has a market cap of $393.37 billion, a price-to-earnings ratio of 10.19, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.66 EPS. Equities analysts anticipate that Johnson & Johnson will post 10 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. Johnson & Johnson’s payout ratio is currently 30.92%.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.